Citigroup’s Kiora Pharmaceuticals KPRX Stock Holding History

Citigroup’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,884	Closed	-$10.9K	–	6272
2025 Q3	$10.9K	Buy	3,884 +3,849	+10,997%	+$10.6K	﹤0.01%	4997
2025 Q2	$101	Buy	+35	New	+$107	﹤0.01%	5513
2022 Q2	–	Sell	-3	Closed	-$1K	–	6447
2022 Q1	$1K	Buy	+3	New	+$784	﹤0.01%	6184
2016 Q2	–	Hold	0	–	–	–	7238
2016 Q1	–	Hold	0	–	–	–	7604

Other funds holding KPRX

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citigroup's KPRX Position: Q4 2025 in Review

Citigroup sold out of Kiora Pharmaceuticals (KPRX) in Q4 2025, closing a stake of 3,884 shares — an estimated $10.9K sold.

Citigroup first reported a position in KPRX in Q1 2022 and held it in 3 quarters. The position peaked at $10.9K in Q3 2025. 19 funds tracked by Wall St. Rank hold KPRX as of Q4 2025.

Citigroup reported no remaining Kiora Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Citigroup sold 3,884 Kiora Pharmaceuticals shares in Q4 2025, an estimated $10.9K.
Citigroup first reported a position in Kiora Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Citigroup's Kiora Pharmaceuticals position peaked at $10.9K in Q3 2025.
19 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.